文献速递血脂与心血管预防冠心病

单基因与多基因高胆固醇血症与动脉粥样硬化性心血管疾病风险的关联

Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease.
PubMed 文献 · JAMA Cardiol · 2020-01-01

基于英国生物银行48 741名40-69岁参与者的遗传关联研究,比较单基因家族性高胆固醇血症(FH)、多基因高胆固醇血症与未确定原因高胆固醇血症者的心血管事件风险。在LDL-C水平相当的情况下,单基因FH(HR 1.93)和多基因高胆固醇血症(HR 1.26)均与心血管事件风险增加独立相关。

要点

  • 单基因FH患病率约0.57%(1/176),55岁前心血管事件风险显著高于无单基因FH者(6.1% vs 2.0%)。
  • LDL-C水平相当时,单基因FH的心血管风险(HR 1.93)高于多基因高胆固醇血症(HR 1.26)。
  • 明确高胆固醇血症的遗传病因可为风险评估和治疗提供额外预后信息。

核心结论

  • 高胆固醇血症患者中,LDL-C的遗传决定因素可能带来额外的心血管疾病风险。
  • 明确高胆固醇血症的遗传病因可能为治疗提供重要的预后信息。

研究设计与样本

  • 遗传关联、病例对照、队列研究,数据来自英国生物银行2006年3月13日至2010年10月1日招募的40-69岁个体,随访至2017年3月31日。
  • 利用基因分型芯片和外显子组测序数据,鉴定单基因(LDLR、APOB、PCSK9)或多基因高胆固醇血症(基于223个单核苷酸变异计算的LDL-C多基因评分>整个队列第95百分位)。
  • 分析48 741名具有基因分型芯片和外显子组测序数据的个体,平均(SD)年龄56.6(8.0)岁,女性占54.5%(26 541/48 741)。
  • 单基因FH 277例(0.57%),多基因高胆固醇血症2 379例,原因未明高胆固醇血症2 232例。

主要发现

  • 单基因FH患者55岁或以下发生动脉粥样硬化性心血管事件的比例显著高于无单基因FH者(17/277 [6.1%] vs 988/48 464 [2.0%];P < .001)。
  • 与一般人群相比,单基因和多基因高胆固醇血症均与心血管事件风险增加相关。
  • 在LDL-C水平相当的个体中,与原因未明高胆固醇血症者相比,单基因FH(HR 1.93;95% CI 1.34-2.77;P < .001)和多基因高胆固醇血症(HR 1.26;95% CI 1.03-1.55;P = .03)均与心血管事件风险增加显著相关。

临床怎么用

  • 对高胆固醇血症患者,可考虑明确遗传病因以进行更精准的风险分层。
  • 单基因FH患者即使LDL-C水平与多基因或未明原因者相当,也应视为更高危人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Monogenic familial hypercholesterolemia (FH) is associated with lifelong elevations in low-density lipoprotein cholesterol (LDL-C) levels and increased risk of atherosclerotic cardiovascular disease (CVD). However, many individuals with hypercholesterolemia have a polygenic rather than a monogenic cause for their condition. It is unclear if a genetic variant for hypercholesterolemia alters the risk of CVD. OBJECTIVES: To assess whether a genetic variant for hypercholesterolemia alters the risk of atherosclerotic CVD and to evaluate how this risk compares with that of nongenetic hypercholesterolemia. DESIGN, SETTING, AND PARTICIPANTS: In this genetic-association, case-control, cohort study, individuals aged 40 to 69 years were recruited by the UK Biobank from across the United Kingdom between March 13, 2006, and October 1, 2010, and followed up until March 31, 2017. Genotyping array and exome sequencing data from the UK Biobank cohort were used to identify individuals with monogenic (LDLR, APOB, and PCSK9) or polygenic hypercholesterolemia (LDL-C polygenic score >95th percentile based on 223 single-nucleotide variants in the entire cohort). The data were analyzed from July 1, 2019, to December 30, 2019. MAIN OUTCOMES AND MEASURES: The study investigated the association of genotype with the risk of coronary and carotid revascularization, myocardial infarction, ischemic stroke, and all-cause mortality among the overall study population and among participants with monogenic FH (n = 277), polygenic hypercholesterolemia (n = 2379), or hypercholesterolemia with undetermined cause (n = 2232) at comparable levels of LDL-C measured at study enrollment. RESULTS: For the 48 741 individuals with genotyping array and exome sequencing data, the mean (SD) age was 56.6 (8.0) years, and 54.5% were female (n = 26 541 of 48 741). A monogenic FH variant for hypercholesterolemia was found in 277 individuals (0.57%, 1 in 176 individuals). Participants with monogenic FH were significantly more likely than those without monogenic FH to experience an atherosclerotic CVD event at 55 years or younger (17 of 277 [6.1%] vs 988 of 48 464 [2.0%]; P < .001). Compared with the general population, both monogenic and polygenic hypercholesterolemia were associated with an increased risk of CVD events. Moreover, among individuals with comparable levels of LDL-C, both monogenic (hazard ratio, 1.93; 95% CI, 1.34-2.77; P < .001) and polygenic hypercholesterolemia (hazard ratio, 1.26; 95% CI, 1.03-1.55; P = .03) were significantly associated with an increased risk of CVD events compared with the risk of such events in individuals with hypercholesterolemia without an identified genetic cause. CONCLUSIONS AND RELEVANCE: The findings of this study suggest that among individuals with hypercholesterolemia, genetic determinants of LDL-C levels may impose additional risk of CVD. Thus, understanding the possible genetic cause of hypercholesterolemia may provide important prognostic information to treat patients.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Trinder M, Francis GA, Brunham LR, et al. Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2020. PMID: 32049305. doi:10.1001/jamacardio.2019.5954

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。